• 제목/요약/키워드: TCF protocol

검색결과 2건 처리시간 0.019초

TFRC 혼잡제어 프로토콜 공정성 개선 방안 (Improving the Fairness of TFRC Congestion Control Protocol)

  • 조경연;장주욱
    • 한국정보과학회:학술대회논문집
    • /
    • 한국정보과학회 2001년도 가을 학술발표논문집 Vol.28 No.2 (3)
    • /
    • pp.355-357
    • /
    • 2001
  • TFRC(TCF-friendly Rate Control) 혼잡제어는 연속적인 재생을 필요로 하는 멀티미디어 서비스를 위한 TCP-friendly 알고리즘이다. 이러한 TCP-friendly 알고리즘의 성능을 결정하는 가장 중요한 요인으로 기존 TCP 혼잡제어 알고리즘을 이용하는 트래픽과의 전송대역폭에 대한 공정성(fairness)이다. TFRC 혼잡제어 알고리즘에서는 이러한 공정성을 만족시키기 위하여 TCP를 모델링한 식에 의하여 전송률을 결정한다. 그러나 TFRC 혼잡제어는 혼잡이 심한 네트워크 상황에서는 공정성이 급격히 떨어진다. 본 논문에서는 TFRC 혼잡제어알고리즘의 전송률 결정방법의 개선을 통하여, 높은 손실률을 보이는 혼잡한 네트워크상황에서 공정성이 떨어지는 문제를 해결한다.

  • PDF

Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey

  • Teker, Fatih;Yilmaz, Bahiddin;Kemal, Yasemin;Kut, Engin;Yucel, Idris
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권16호
    • /
    • pp.6727-6732
    • /
    • 2014
  • Objectives: Advanced gastric cancer (AGC) patients have a poor prognosis. The best benefit of chemotherapy is usually achieved by first line setting. Very few studies have compared combination regimens. This study was designed to compare two combination regimens. Methods: Patients with advanced gastric cancer receiving first line chemotherapy were retrospectively collected, and divided into two groups, receiving DCF (docetaxel, cisplatin and fluorouracil) or ECF (epirubicin, cisplatin and fluorouracil) regimens. Data were collected for the retrospective analysis in a single center. Results: Eighty-six patients were eligible for analysis. Median overall survival (OS) was 10.0 months in the ECF group and 11.0 months in the DCF group (p=0.31). Median progression free survival (PFS) for ECF and DCF was equal at 6.0 months. Second line chemotherapy were administered in more than one third of patients. Both regimens had similar toxicity. Conclusions: This is the first study investigating the outcomes of gastric cancer chemotherapy in this region. ECF and DCF regimens have similar efficacy and a similar tolerability profile for first line treatment of advanced gastric cancer. The decision of the first line chemotherapy in advanced gastric cancer could be improved with patient selection according to clinical parameters and molecular markers.